Staff Profile

I am a consultant nephrologist at Newcastle upon Tyne Hospitals NHS Foundation Trust and associate clinical lecturer at the Institute of Cellular Medicine. My clinical time is divided between the National Renal Complement Therapeutics Centre and Renal Services.

My main clinical role is providing expert advice for the diagnosis and management of atypical haemolytic uraemic syndrome (aHUS) and C3 glomerulopathy (C3G) nationally. This includes implementing the NHS England Highly Specialised Services policies on the use of eculizumab in the treatment of these conditions. (aHUS / C3G) 

Leadership Roles: Clinical lead for C3G within the National Renal Complement Therapeutic Centre / Member of the MPGN/C3G Rare Disease Group

I undertook my speciality training in renal medicine in the North East (2008-2017), during which I completed an extensive period of research in complement-mediated renal diseases as a MRC Clinical Research Training Fellow (2013-2016) and NIHR Academic Clinical Lecturer (2016-2017).

In my research period, I studied complement abnormalities in aHUS, C3G and membranoproliferative glomerulonephritis (MPGN), through laboratory and clinical research methods.

I have published my work in top-ranking nephrology journals (J Am Soc Nephol / Kidney Int) and presented my work in national and international meetings.

I was awarded a Doctoral Thesis Prize for my PhD in 2016 and the prestigious Renal Association (Young Investigator) Raine Award in 2017. 

• Wong EKS, Kavanagh D. Diseases of complement dysregulation—an overview. Seminars in Immunopathology 2018, 40(1), 49-64.
• Farmery JHR, Smith ML, NIHR BioResource - Rare Diseases, (group includes, Chinnery P, Corris PA, Emmerson I, Horvath R, Johnson S, Shipley D, Wong EKS), Lynch AG. Telomerecat: A ploidy-agnostic method for estimating telomere length from whole genome sequencing data. Scientific Reports 2018, 8, 1300.
• Kerr H, Wong E, Makou E, Yang Y, Marchbank K, Kavanagh D, Richards A, Herbert A, Barlow P. Disease-linked mutations in factor H reveal pivotal role of cofactor activity in self surface-selective regulation of complement activation. Journal of Biological Chemistry 2017, 292, 13345-13360.
• Brocklebank V, Johnson S, Sheerin TP, Marks SD, Gilbert RD, Tyerman K, Kinoshita M, Awan A, Kaur A, Webb N, Hegde S, Finlay E, Fitzpatrick M, Walsh P, Wong EKS, Booth C, Kerecuk L, Salama A, Almond M, Inward C, Goodship TH, Sheerin N, Marchbank KJ, Kavanagh D. Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland. Kidney International 2017, 92(5), Pages 1261-1271.
• Bruel A, Kavanagh D, Noris M, Delmas Y, Wong E, Bresin E, Provôt F, Brocklebank V, Mele C, Remuzzi G, Loirat C, Frémeaux-Bacchi V, Fakhouri F. Hemolytic Uremic Syndrome in Pregnancy and Post-Partum. Clinical Journal of the American Society of Nephrology 2017, 12(8), 1237-1247.
• Challis RC, Araujo GSR, Wong EKS, Anderson HE, Awan A, Dorman AM, Waldron M, Wilson V, Brocklebank V, Strain L, Morgan BP, Harris CL, Marchbank KJ, Goodship THJ, Kavanagh D. A De Novo Deletion in the Regulators of Complement Activation Cluster Producing a Hybrid Complement Factor H/Complement Factor H–Related 3 Gene in Atypical Hemolytic Uremic Syndrome. Journal of the American Society of Nephrology 2016, 27(6), 1617-1624.
• Wong EKS, Kavanagh D. Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Translational Research 2015, 165(2), 306-320.
• Nichols EM, Barbour TD, Kerr H, Pappworth IY, Wong EKS, Palmer J, Sheerin NS, Herbert A, Barlow PN, Pickering MC, Marchbank KJ. FH1-5^(18-20) ameliorates experimental C3 glomerulopathy; generation and testing of a murine version for further pre-clinical experiments. In: 15th European Meeting on Complement in Human Disease 2015. 2015, Uppsala, Sweden: Elsevier.
• Wong E, Challis R, Sheerin N, Johnson S, Kavanagh D, Goodship TH. Patient stratification and therapy in atypical haemolytic uraemic syndrome (aHUS). Immunobiology 2015.
• Wong EKS, Marchbank K, Pappworth I, Walters R, Lomax-Browne H, Harris C, Morgan P, Pickering M, Goodship THJ, Malcomson R, Cook T, Johnson S, MPGN C3G Rare Dis Grp. The national study of membranoproliferative glomerulonephrtis and C3 glomerulopathy - characterisation of the paediatric cohort. In: 52nd ERA-EDTA Congress. 2015, London, UK: Oxford University Press.
• Brocklebank V, Wong EKS, Fielding R, Goodship THJ, Kavanagh D. Atypical haemolytic uraemic syndrome associated with a CD46 mutation triggered by Shigella flexneri. Clinical Kidney Journal 2014, 7(3), 286-288.
• Wong EKS, Husain A, Sayer JA. Sarcoidosis presenting with hypercalcaemia following withdrawal of long-term immunosuppression in renal transplantation. Oxford Medical Case Reports 2014, 2014(5), 86-88.
• Yu Y, Triebwasser MP, Wong EKS, Schramm EC, Thomas B, Reynolds R, Mardis ER, Atkinson JP, Daly M, Raychaudhuri S, Kavanagh D, Seddon JM. Whole-exome sequencing identifies rare, functional CFH variants in families with macular degeneration. Human Molecular Genetics 2014, 23(19), 5283-5293.
• Wong EKS, Goodship THJ, Kavanagh D. Complement therapy in atypical haemolytic uraemic syndrome (aHUS). Molecular Immunology 2013, 56(3), 199-212.